Researchers Unveil ‘Blueprint’ To Guide Next Steps In TB Vaccine Development

“On Tuesday, a global alliance of researchers and scientists — led by the Stop TB Partnership, an umbrella group of health groups — unveiled a ‘blueprint‘ to develop a new vaccine [against tuberculosis (TB)] that aims to disrupt transmission in hard-hit countries and communities,” the Wall Street Journal reports. “The blueprint calls for the groups to work together to test new vaccine candidates, and to coordinate fundraising for expansive and expensive human trials, representing the first comprehensive plan of the sort,” the news service writes (Wonacott, 3/20).

“The fresh impetus to the research comes as scientists await the release in early 2013 of results from the world’s most advanced TB vaccine trial — one of 12 currently underway,” Agence France-Presse notes (3/20). “Mike Brennan, an adviser to the U.S.-based Aeras non-profit TB research group, said the new worldwide blueprint for a plan of action followed ‘tremendous progress’ already made in the past decade,” adding that “[t]he South African trials and work in other countries now mark ‘a rallying point for one of the world’s deadliest diseases’ that includes strains resistant to conventional drugs,” the Associated Press/Washington Post writes (3/20).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.